<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02414321</url>
  </required_header>
  <id_info>
    <org_study_id>NL51128.042.15</org_study_id>
    <nct_id>NCT02414321</nct_id>
  </id_info>
  <brief_title>The Role of the Pulmonary Vasculature in the Fontan Circulation</brief_title>
  <official_title>The Role of the Pulmonary Vasculature in the Fontan Circulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to explore the structural and functional characteristics of the pulmonary
      vasculature in adult Fontan patients.

      Objectives:

        -  Determine the effect of pulmonary vasodilatation on indexed cardiac output during
           simulated exercise.

        -  Characterization of structural properties of small pulmonary arteries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale:

      The Fontan circulation is a palliation for patients with a functionally univentricular heart.
      The Fontan circulation is characterized by impaired exercise capacity and gradual attrition
      over time. To date treatment options are extremely limited. It has been proposed that
      pulmonary vascular resistance (PVR) is the controlling and limiting factor of cardiac output
      in the Fontan circulation. Remodeling of the pulmonary vasculature and increasing PVR are
      possible key factors in the long term failure of the Fontan circulation. Optical Coherence
      Tomography (OCT) is an intravascular imaging modality used for structural characterization of
      blood vessels. Nitric oxide is a pulmonary vasodilator used in pulmonary vascular response
      tests, aimed at lowering PVR which may improve cardiac output in the Fontan circulation.
      These two diagnostic procedures are tools to study the structural and functional
      characteristics of the pulmonary vasculature in the Fontan circulation. The results of this
      study could identify the pulmonary circulation as a future treatment target in Fontan
      patients and may provide clues for new therapeutic treatment strategies to improve the long
      term outcome of these patients.

      Study procedure:

      The study protocol will be performed during a clinically indicated cardiac catheterization.
      In the context of this study additional measurements will be performed which will include a
      pulmonary vascular response test, trans-thoracic echocardiography and pulmonary artery OCT
      measurements.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>change in indexed cardiac output between baseline and after pulmonary vasodilatation</measure>
    <time_frame>change in indexed cardiac output between baseline and after 10 minutes of pulmonary vasodilatation at heart catheterization</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>number of intimal lesions in small pulmonary arteries</measure>
    <time_frame>baseline at heart catheterization</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Congenital Heart Disease</condition>
  <condition>Fontan Operation</condition>
  <condition>Pulmonary Vascular Resistance</condition>
  <condition>Pulmonary Vascular Remodeling</condition>
  <arm_group>
    <arm_group_label>Fontan group</arm_group_label>
    <description>Right heart catheterization:
pulmonary artery OCT analysis
dobutamine stress test
pulmonary vascular response test (nitric oxide)
trans-thoracic echocardiography</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Right heart catheterization:
- pulmonary artery OCT analysis</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All adult patients (≥18 years), who attend the University Medical Center Groningen for
        follow-up after a Fontan completion.

        Additionally 5 adult patients (≥18 years) without a Fontan circulation and without a
        univentricular heart-like diagnosis but with a clinical indication for right heart
        catheterization and normal values at right heart catheterization measurements will be
        included to serve as controls for the pulmonary artery OCT analysis.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

        Fontan group

          -  written informed consent

          -  Clinical indication for cardiac catheterization

        Control group

          -  written informed consent

          -  Clinical indication for right heart catheterization

          -  Absence of pulmonary vascular disease

          -  Normal pulmonary vascular hemodynamic profile

        Exclusion criteria:

        Fontan group

          -  Standard exclusion criteria for cardiac catheterization

          -  Obstruction in Fontan conduit

          -  Inability to measure a reliable cardiac index and PVR (rhythm instability, hemodynamic
             or anatomic reasons)

        Control Group

        - No specific exclusion criteria apart from the standard exclusion criteria for right heart
        catheterization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rolf M Berger, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Floris-Jan S Ridderbos, MD</last_name>
    <phone>+31503611506</phone>
    <email>f.j.s.ridderbos@umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elke S Hoendermis, MD PhD</last_name>
    <phone>+31503612359</phone>
    <email>e.s.hoendermis@umcg.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rolf MF Berger, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elke S Hoendermis, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Floris-Jan S Ridderbos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Fontan F, Baudet E. Surgical repair of tricuspid atresia. Thorax. 1971 May;26(3):240-8.</citation>
    <PMID>5089489</PMID>
  </reference>
  <reference>
    <citation>Wolff D, van Melle JP, Ebels T, Hillege H, van Slooten YJ, Berger RM. Trends in mortality (1975-2011) after one- and two-stage Fontan surgery, including bidirectional Glenn through Fontan completion. Eur J Cardiothorac Surg. 2014 Apr;45(4):602-9. doi: 10.1093/ejcts/ezt461. Epub 2013 Sep 25.</citation>
    <PMID>24067749</PMID>
  </reference>
  <reference>
    <citation>de Leval MR, Deanfield JE. Four decades of Fontan palliation. Nat Rev Cardiol. 2010 Sep;7(9):520-7. doi: 10.1038/nrcardio.2010.99. Epub 2010 Jun 29. Review.</citation>
    <PMID>20585329</PMID>
  </reference>
  <reference>
    <citation>Gewillig M, Brown SC, Eyskens B, Heying R, Ganame J, Budts W, La Gerche A, Gorenflo M. The Fontan circulation: who controls cardiac output? Interact Cardiovasc Thorac Surg. 2010 Mar;10(3):428-33. doi: 10.1510/icvts.2009.218594. Epub 2009 Dec 7. Review.</citation>
    <PMID>19995891</PMID>
  </reference>
  <reference>
    <citation>Goldberg DJ, Avitabile CM, McBride MG, Paridon SM. Exercise capacity in the Fontan circulation. Cardiol Young. 2013 Dec;23(6):824-30. doi: 10.1017/S1047951113001649.</citation>
    <PMID>24401254</PMID>
  </reference>
  <reference>
    <citation>Khambadkone S, Li J, de Leval MR, Cullen S, Deanfield JE, Redington AN. Basal pulmonary vascular resistance and nitric oxide responsiveness late after Fontan-type operation. Circulation. 2003 Jul 1;107(25):3204-8. Epub 2003 Jun 23.</citation>
    <PMID>12821557</PMID>
  </reference>
  <reference>
    <citation>Ridderbos FJ, Wolff D, Timmer A, van Melle JP, Ebels T, Dickinson MG, Timens W, Berger RM. Adverse pulmonary vascular remodeling in the Fontan circulation. J Heart Lung Transplant. 2015 Mar;34(3):404-13. doi: 10.1016/j.healun.2015.01.005. Epub 2015 Jan 16.</citation>
    <PMID>25813767</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2015</study_first_submitted>
  <study_first_submitted_qc>April 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2015</study_first_posted>
  <last_update_submitted>December 23, 2017</last_update_submitted>
  <last_update_submitted_qc>December 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Prof. dr. R.M.F. Berger</investigator_full_name>
    <investigator_title>Professor and Head of Department of Pediatric Cardiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Vascular Remodeling</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

